New diabetes pill shows early promise in small study
NCT ID NCT00707954
First seen Jan 08, 2026 · Last updated Jun 21, 2026 · Updated 24 times
Summary
This early-stage study tested an experimental drug called TA-7284 in 61 adults with type 2 diabetes. Participants took different doses (25 to 400 mg) or a placebo daily for 15 days. The goal was to check the drug's safety, how the body processes it, and its effects on blood sugar and insulin. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
P-One Clinic
Hachiōji, Tokyo-to, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TA-7284 (an experimental drug for type 2 diabetes)
What this could lead to
If successful, this could lead to a new daily pill to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early-phase trial with only 61 participants, so the drug may not prove safe or effective in larger studies. Side effects are possible and not yet fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.